Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | UGCG | Q16739 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24370924 | 1.00 | CETP (0.35) | CETPEGLN2GPR119ARIRAK4 | |
| SCHEMBL29158603 | 0.91 | CTSS (0.36) | CETPEGLN2GPR119ARIRAK4 | |
| SCHEMBL29158599 | 0.91 | CTSS (0.36) | CETPEGLN2GPR119ARIRAK4 | |
| SCHEMBL23085662 | 0.91 | CTSS (0.36) | CETPEGLN2GPR119ARIRAK4 | |
| SCHEMBL30798694 | 0.91 | CTSS (0.36) | CETPEGLN2GPR119ARIRAK4 | |
| SCHEMBL24370934 | 0.89 | EGLN2 (0.36) | CETPEGLN2GPR119ARIRAK4 | |
| SCHEMBL24370930 | 0.89 | IRAK4 (0.35) | CETPEGLN2GPR119ARIRAK4 | |
| SCHEMBL23085670 | 0.86 | USP30 (0.39) | CETPEGLN2GPR119ARUSP30 | |
| SCHEMBL29158595 | 0.86 | USP30 (0.39) | CETPEGLN2GPR119ARUSP30 | |
| SCHEMBL29770996 | 0.86 | USP30 (0.39) | CETPEGLN2GPR119ARUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022084479-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-04-28 | — | — | WO | disclosed |